TITLE

Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole

AUTHOR(S)
Hendset, Magnhild; Hermann, Monica; Lunde, Hilde; Refsum, Helge; Molden, Espen
PUB. DATE
December 2007
SOURCE
European Journal of Clinical Pharmacology;Dec2007, Vol. 63 Issue 12, p1147
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Aripiprazole is an atypical antipsychotic drug which is metabolized by the polymorphic enzyme cytochrome P450 2D6 (CYP2D6). The aim of the present study was to investigate the impact of the CYP2D6 genotype on serum concentrations of aripiprazole (ARI) and to determine the sum of ARI and the active metabolite dehydroaripiprazole (DARI) in psychiatric patients. Data on steady-state serum concentrations and the CYP2D6 genotypes of patients treated with ARI were extracted from a routine therapeutic drug monitoring database. The 62 patients included in the analysis were stratified into the following subgroups according to CYP2D6 genotype: *1/*1 (homozygous extensive metabolizers, EMs; n = 37), *1/*3–6 (heterozygous extensive metabolizers, HEMs; n = 17) and *3–6/*3–6 (poor metabolizers, PMs; n = 8). Dose-adjusted serum concentrations (C/D ratios) of ARI and ARI + DARI were compared between the subgroups. The median serum concentration of ARI was 1.7-fold higher in PMs than in EMs (45.5 vs. 26.3 n M/mg, p < 0.01). The observed serum concentration of the active sum of ARI + DARI was 1.5-fold higher in PMs than in EMs (53.9 vs. 37.0 n M/mg, p < 0.05). Numerical differences in serum concentrations between HEMs and EMs were less pronounced, but statistically significant for both ARI ( p < 0.05) and ARI + DARI ( p < 0.05). The present study demonstrates that serum concentrations of both ARI and the active sum of ARI + DARI in psychiatric patients were significantly affected by CYP2D6 genotype. The observed differences in median C/D ratios indicate that PMs typically need 30–40% lower doses to achieve a similar steady-state serum concentration as EMs.
ACCESSION #
27419846

 

Related Articles

  • Interactions between the cytochrome P450 system and the second-generation antipsychotics. Prior, Trevor I.; Baker, Glen B. // Journal of Psychiatry & Neuroscience;Mar2003, Vol. 28 Issue 2, p99 

    Awareness of the metabolism of second-generation antipsychotics by the cytochrome P450 (CYP) system can inform the clinician about how to avoid and manage drug-drug interactions involving these enzymes. Clozapine is metabolized primarily by CYPIA2, with additional contributions by CYP2CI9,...

  • Cytochrome P450 Phenotyping/Genotyping in Patients Receiving Antipsychotics: Useful Aid to Prescribing? Dahl, M-L. // Clinical Pharmacokinetics;May2002, Vol. 41 Issue 7, p453 

    Many antipsychotics, including perphenazine, zuclopenthixol, thioridazine, haloperidol and risperidone, are metabolised to a significant extent by the polymorphic cytochrome P450 (CYP) 2D6, which shows large interindividual variation in activity. Significant relationships between CYP2D6 genotype...

  • Fatal intoxication cases: cytochromeP 4502D6 and 2C19 genotype distributions. Zackrisson, A.L.; Holmgren, P.; Gladh, A.B.; Ahlner, J.; Lindblom, B. // European Journal of Clinical Pharmacology;Oct2004, Vol. 60 Issue 8, p547 

    Objective: Many commonly used pharmaceuticals, such as antidepressants and neuroleptics as well as some illegal drugs, are metabolised by the cytochrome P 450 enzyme debrisoquine 4-hydroxylase (CYP2D6). Of Caucasians, 7-10% lack this enzyme, which can, upon administration of drugs in normal...

  • An Evaluation of Ondansetron Binding Interactions with Human Cytochrome P450 Enzymes CYP3A4 and CYP2D6. Lewis, David F. V.; Ito, Yuko; Eddershaw, Peter J.; Dickins, Maurice; Goldfarb, Peter S. // Drug Metabolism Letters;Jan2010, Vol. 4 Issue 1, p25 

    The results of an evaluation study of ondansetron binding to human cytochromes P450 CYP3A4 and CYP2D6 is reported. The methodology includes NMR spectroscopic measurements of substrate to heme iron distances together with molecular modelling of the enzyme-substrate interactions. It is shown that...

  • Prevalence of CYP2D6-metabolised drug use varies.  // PharmacoEconomics & Outcomes News;5/5/2007, Issue 527, p7 

    The article discusses research being done on the prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations. It references a study by H. Mulder, E. R. Heerdink, F. W. Wilmink et al, published in the March 2007 issue of "Annals of Pharmacotherapy." The...

  • Cytochrome P450 2D6 Genotype Variation and Venlafaxine Dosage. McAlpine, Donald E.; O'Kane, Dennis J.; Black, John L.; Mrazek, David A. // Mayo Clinic Proceedings;Sep2007, Vol. 82 Issue 9, p1065 

    OBJECTIVE: To determine whether the presence or absence of a fully functioning cytochrome P450 2D6 allele was associated with the dosage of the antidepressant drug veniafaxine in patients who had either adverse effects or absence of a therapeutic response to treatment with the immediate release...

  • Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia. Doki, Kosuke; Homma, Masato; Kuga, Keisuke; Kusano, Kazutomi; Watanabe, Shigeyuki; Yamaguchi, Iwao; Kohda, Yukinao // European Journal of Clinical Pharmacology;Nov2006, Vol. 62 Issue 11, p919 

    To examine the effect of CYP2D6 genotype on the pharmacokinetics of flecainide, we conducted a population pharmacokinetic analysis of the data collected during routine therapeutic drug monitoring of Japanese patients with supraventricular tachyarrhythmia. Population analysis was performed on...

  • Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance. Shu-Feng Zhou // Clinical Pharmacokinetics;2009, Vol. 48 Issue 11, p689 

    Cytochrome P450 (CYP) 2D6 is one of the most investigated CYPs in relation to genetic polymorphism, but accounts for only a small percentage of all hepatic CYPs (~2-4%). There is a large interindividual variation in the enzyme activity of CYP2D6. The enzyme is largely non-inducible and...

  • Metabolism of Atypical Antipsychotics: Involvement of Cytochrome P450 Enzymes and Relevance for Drug-Drug Interactions. Urichuk, Liana; Prior, Trevor I.; Dursun, Serdaqr; Baker, Glen // Current Drug Metabolism;Jun2008, Vol. 9 Issue 5, p410 

    The involvement of cytochrome P450 (CYP) enzymes in the metabolism of the atypical (second-generation) antipsychotics clozapine, risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, paliperidone and amisulpride is reviewed, and the possible relevance of this metabolism to drug-drug...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics